Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Cell Therapeutics Inc announces interim results from phase 2 tosedostat trial


Tuesday, 10 Dec 2013 01:30am EST 

Cell Therapeutics Inc:Says promising interim results from an investigator-initiated Phase 2 clinical trial of tosedostat in combination with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).Says phase 2 trial was designed to test the efficacy of tosedostat in combination with low intensity therapy for older patients with previously untreated AML or high-risk MDS not considered candidates for standard intensive therapy.Says Patients were randomized to treatment with tosedostat in combination with either cytarabine or decitabine.Says 14 out of 26 (54 pct) patients in this cohort had either a complete response (CR; n=10, 39 pct) or complete response with incomplete blood count recovery (CRi; n=4, 15 pct).Says seven (50 pct) of the 14 CR/CRi were achieved in patients with poor-risk cytogenetic features.Says study achieved its primary objective with 21 (82 pct) patients alive at four months. 

Company Quote

2.66
0.01 +0.38%
4:00pm EDT